Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Idiopathic copper-associated cirrhosis is a rare copper-overload liver disease characterized by a rapidly progressive liver cirrhosis from the first few years of life leading to hepatic insufficiency and harboring a specific pathological aspect: pericellular fibrosis, inflammatory infiltration, hepatocyte necrosis, absence of steatosis, poor regeneration and histochemical copper staining.
Features include always present findings: Liver scarring (cirrhosis) (cirrhosis) and Copper accumulation in liver; and common findings: Hepatic steatosis, Increased urinary copper concentration, and Increased circulating copper concentration.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 3 | Liver scarring (cirrhosis) (cirrhosis), Copper accumulation in liver, Hepatic steatosis |
Biomarker and diagnostic research for idiopathic copper-associated cirrhosis has been reported in the published literature.
Phenotype severity distribution: 2 always present features, 3 common features.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for idiopathic copper-associated cirrhosis.
3 publications have been identified in PubMed for idiopathic copper-associated cirrhosis. Research spans Diagnostic / Biomarker (33%), Review / Meta-Analysis (33%), and Gene Therapy / Novel Therapeutics (33%).
Pandey R (2026). [PMID: 41406573](https://pubmed.ncbi.nlm.nih.gov/41406573/). *Redox biology*. [Gene Therapy / Novel Therapeutics]
Tinoco-Nájera A (2026). [PMID: 41072468](https://pubmed.ncbi.nlm.nih.gov/41072468/). *American journal of veterinary research*. [Diagnostic / Biomarker]
Teschke R (2024). [PMID: 38928368](https://pubmed.ncbi.nlm.nih.gov/38928368/). *International journal of molecular sciences*. [Review / Meta-Analysis]
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 11:51 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Lab test results |
2 |
Increased urinary copper concentration, Increased circulating copper concentration |
Kidneys and urinary system | 1 | Increased urinary copper concentration |
AI-curated news mentioning idiopathic copper-associated cirrhosis
Updated Sep 11, 2026
A recent study highlights the clinico-radiological differences between porto-sinusoidal vascular disorder and cirrhosis, providing insights that could enhance diagnostic accuracy. This research may aid in distinguishing these conditions, which can have overlapping symptoms.
New expert recommendations have been published for managing portal hypertension in patients with cirrhosis. These guidelines aim to improve clinical practices and patient outcomes in this complex condition.
A recent study highlights progressive multifocal leukoencephalopathy as a rare neurological disorder linked to cirrhosis. This discovery emphasizes the need for awareness and further research into the implications of this association.